<DOC>
	<DOCNO>NCT00167167</DOCNO>
	<brief_summary>In study hypothesis infusion donor lymphocyte immune cell subject 's bone marrow donor activate subject 's immune system attack cancer .</brief_summary>
	<brief_title>Donor Lymphocyte Infusion ( DLI ) Relapsed ( Post Transplant ) Leukemia</brief_title>
	<detailed_description>We collect immune cell lymphocytes donor 's blood use cell separator . The blood lymphocytes give subject catheter . If subject complication first course infusion , may decide give `` lymphocyte '' aa second time subject remission attempt prevent disease relapse . A bone marrow test take prior infusion lymphocyte part clinical evaluation receive treatment . After lymphocyte infusion , bone marrow examine every three month first year monitor progress therapy .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>Patients CML , AML , MDS ALL relapse relate unrelated donor allogeneic marrow transplantation . Patients must within one year identification relapse beyond time period , must evidence donor DNA RFLP cytogenetics . Patients may evidence relapse base molecular , cytogenetic morphologic criterion . CML patient must cytogenetic evidence relapse Ph negative start , obvious evidence relapse minimal residual disease . Patients must &lt; 30 % marrow blast marrow biopsy perform within two week first donor lymphocyte infusion . Patients &gt; 30 % blast become eligible donor lymphocyte reinduction standard therapy regimen . Patients AML , MDS ALL achieve CR standard therapy regimen eligible protocol . Patients relapse initial disease develop second malignancy relate unrelated donor allogeneic marrow transplantation initial diagnosis ( limited CLL , lymphoma , myeloma , juvenile CML , sarcoma , breast cancer ) may also include protocol . Patients eligible without adjunct chemotherapy radiation therapy . Posttransplant lymphoma ( often refer EBVassociated lymphoma ) eligible donor leukocyte infusion protocol . Treatment donor leukocyte protocol restrict malignant disease . Graft failure relapse nonmalignant disorder exclude receive donor leukocyte infusion protocol . Autologous transplant patient relapse eligible protocol . Patients malignant disease amenable curative therapy eligible ( i.e . skin cancer ) . Patients concurrent sign acute chronic graftversushost disease require ongoing treatment time relapse ineligible . Patients &gt; 30 % marrow blast time therapy ineligible . Patients prednisone , cyclosporine , Imuran immunosuppressive medication eligible medication discontinue least 2 week without flare GVHD . CML patient complete cytogenetic remission bcr/abl positive PCR eligible .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Donor Lymphocyte Infusion</keyword>
	<keyword>relapse</keyword>
	<keyword>post-transplant</keyword>
</DOC>